sub:assertion { d:DB05011v:identifier "DB05011" ; v:namespace "drugbank" ; v:uri "http://bio2rdf.org/drugbank:DB05011" ; v:x-identifiers.org <http://identifiers.org/drugbank/DB05011> ; dv:drugbank-id "DB05011" ; dv:x-cas <http://bio2rdf.org/cas:> ; dct:description "EG004 is a novel product consisting of a local delivery device and a gene-based medicine, being developed to prevent the blocking of veins and arteries that frequently occurs after vascular surgery. The initial target market is haemodialysis graft access surgery, a procedure in which patients whose kidneys have failed have a plastic tube grafted between blood vessels generally in their forearm so that their blood can be regularly filtered using a dialysis machine. EG004 has completed a Phase II trial, this being the first part of the Phase II/III study for which it has received approval from the US Recombinant DNA Advisory Committee (RAC)."@en ; dct:identifier "drugbank:DB05011" ; dct:title "EG004"@en ; adv:Drug ; rdfs:label "EG004 [drugbank:DB05011]"@en ; rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05011> . }